This breast cancer drug is first in new class of chemo agents

News
Article

The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
Related Content
FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

Killian Meara
December 6th 2024
Article

Catch up on important FDA news from the week of December 2.

Looking to the Future of Independent Pharmacy

Looking to the Future of Independent Pharmacy

Miranda Hester
July 13th 2022
Podcast

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

Q&A: How a Community Pharmacist is Helping Other Pharmacies Through Consulting

Q&A: How a Community Pharmacist is Helping Other Pharmacies Through Consulting

Brian Nowosielski;Benjamin Jolley, PharmD
November 25th 2024
Article

Benjamin Jolley, PharmD, pharmacist at Jolley’s Compounding Pharmacy in Salt Lake City, Utah, joined Drug Topics to discuss his career journey.

Podcast: Pharmacy Financing With First Financial Bank

Podcast: Pharmacy Financing With First Financial Bank

January 28th 2022
Podcast

Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara
November 12th 2024
Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

FDA Roundup: Rosacea Treatment, Proposal to Remove Oral Phenylephrine from OTC Products

FDA Roundup: Rosacea Treatment, Proposal to Remove Oral Phenylephrine from OTC Products

Killian Meara
November 8th 2024
Article

Check out these important FDA updates from the week of November 4.

© 2024 MJH Life Sciences

All rights reserved.